Abstract
A large number of IL-1 protein sequences have become available recently from a range of vertebrate species and especially from bony fish. However, 3D structures are still only known for mammalian IL-1. In this review, we use a multiple sequence alignment of all published non-mammalian vertebrate IL-1β proteins to locate the structurally important residues critical for maintaining the βtrefoil fold and we investigate the degree to which functionally important residues involved in receptor binding are conserved across vertebrate species. We find that although there is a high level of variability of positions involved in receptor binding, the mode of binding and overall shape of the ligand-receptor complex is probably maintained. This implies that each species has evolved its own unique interleukin-1 signalling system through ligand-receptor co-evolution. Nonetheless, the IL-1β processing mechanism in non-mammalian vertebrates remains unclear because, with the exception of three bony fish, all non-mammalian IL-1β sequences discovered so far lack an ICE (Interleukin Converting Enzyme) cut site. The IL-1 system has become an important drug target because of its significance in inflammatory diseases. Research on peptides derived from IL-1β has identified peptides that possess agonist activity in humans and in trout, and peptides with antagonist activity. The agonist peptides map to two distinct loop regions of IL-1β that are known to interact with the flexible domain III of the corresponding receptor. Further analysis of the IL-1 system may prove useful in engineering IL-1 with improved features and in suggesting new avenues for therapeutic intervention.
Keywords: interleukin-1, trefoil fold, ice cut site, interleukin-1 receptor, interleukin-1 receptor accessory protein, comparative immunology
Current Pharmaceutical Design
Title: Analysis of Fish IL-1β and Derived Peptide Sequences Indicates Conserved Structures with Species-Specific IL-1 Receptor Binding: Implications for Pharmacological Design
Volume: 10 Issue: 31
Author(s): Antonis I. Koussounadis, David W. Ritchie, Graham J.L. Kemp and Chris J. Secombes
Affiliation:
Keywords: interleukin-1, trefoil fold, ice cut site, interleukin-1 receptor, interleukin-1 receptor accessory protein, comparative immunology
Abstract: A large number of IL-1 protein sequences have become available recently from a range of vertebrate species and especially from bony fish. However, 3D structures are still only known for mammalian IL-1. In this review, we use a multiple sequence alignment of all published non-mammalian vertebrate IL-1β proteins to locate the structurally important residues critical for maintaining the βtrefoil fold and we investigate the degree to which functionally important residues involved in receptor binding are conserved across vertebrate species. We find that although there is a high level of variability of positions involved in receptor binding, the mode of binding and overall shape of the ligand-receptor complex is probably maintained. This implies that each species has evolved its own unique interleukin-1 signalling system through ligand-receptor co-evolution. Nonetheless, the IL-1β processing mechanism in non-mammalian vertebrates remains unclear because, with the exception of three bony fish, all non-mammalian IL-1β sequences discovered so far lack an ICE (Interleukin Converting Enzyme) cut site. The IL-1 system has become an important drug target because of its significance in inflammatory diseases. Research on peptides derived from IL-1β has identified peptides that possess agonist activity in humans and in trout, and peptides with antagonist activity. The agonist peptides map to two distinct loop regions of IL-1β that are known to interact with the flexible domain III of the corresponding receptor. Further analysis of the IL-1 system may prove useful in engineering IL-1 with improved features and in suggesting new avenues for therapeutic intervention.
Export Options
About this article
Cite this article as:
Koussounadis I. Antonis, Ritchie W. David, Kemp J.L. Graham and Secombes J. Chris, Analysis of Fish IL-1β and Derived Peptide Sequences Indicates Conserved Structures with Species-Specific IL-1 Receptor Binding: Implications for Pharmacological Design, Current Pharmaceutical Design 2004; 10 (31) . https://dx.doi.org/10.2174/1381612043382585
DOI https://dx.doi.org/10.2174/1381612043382585 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Tubulin Polymerization Inhibitor Derived from Thalidomide: Implications for Anti-Myeloma Therapy
Current Medicinal Chemistry Lessons from Viruses: Controlling the Function of Transmembrane Proteins by Interfering Transmembrane Helices
Current Medicinal Chemistry Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Molecular Modeling Applied to Anti-Cancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia
Current Cancer Drug Targets Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1<sup>®</sup> can Overcome Drug Resistance in Osteosarcoma
Current Cancer Drug Targets Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Gene Therapy for Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency
Current Gene Therapy Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry